World's Best Scientists 2026 revealed!
Hiroyoshi Nishikawa

Hiroyoshi Nishikawa

D-Index & Metrics

Immunology

D-Index
68
Citations
28131
World Ranking
2541
National Ranking
100

Hiroyoshi Nishikawa publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Hiroyoshi Nishikawa sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 387 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Hiroyoshi Nishikawa D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Hiroyoshi Nishikawa sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 68 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2020 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Hiroyoshi Nishikawa is affiliated with Nagoya University in Japan and has contributed extensively to the fields of Medicine and Immunology and Microbiology. Their work focuses primarily on oncology, immunology, molecular biology, pulmonary and respiratory medicine, and surgery.

Their research spans important subfields such as:

  • Oncology
  • Immunology
  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Surgery

Main topics in Nishikawa's research include:

  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • T-cell and B-cell Immunology

Significant recent publications include:

  • "Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)" (2020) published in Journal of Clinical Oncology
  • "The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies" (2020) published in Nature Immunology
  • "Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments" (2022) published in Cancer Cell
  • "Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies" (2021) published in Journal for ImmunoTherapy of Cancer
  • "Antitumour immunity regulated by aberrant ERBB family signalling" (2021) published in Nature reviews. Cancer

Frequent co-authors in Nishikawa's work include:

  • Shohei Koyama
  • Yosuke Togashi
  • Daisuke Sugiyama
  • Masashi Wakabayashi
  • Kohei Shitara

The most common venues for their publications are:

  • Journal of Clinical Oncology
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • International Immunology
  • Annals of Oncology

Hiroyoshi Nishikawa has been recognized as a Fellow of the American Association for the Advancement of Science (AAAS) in 2020.

Best Publications

  • Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota

    Koji Atarashi;Takeshi Tanoue;Kenshiro Oshima;Wataru Suda

  • Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

    Eiichi Sato;Sara H. Olson;Jiyoung Ahn;Brian Bundy

  • Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

    Yosuke Togashi;Kohei Shitara;Hiroyoshi Nishikawa

  • Regulatory T cells in tumor immunity

    Hiroyoshi Nishikawa;Shimon Sakaguchi;Shimon Sakaguchi

  • Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

    Yoshihiro Ohue;Hiroyoshi Nishikawa

  • Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.

    Unknown

  • PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

    Takahiro Kamada;Yosuke Togashi;Christopher Tay;Danbee Ha

  • Two FOXP3 + CD4 + T cell subpopulations distinctly control the prognosis of colorectal cancers

    Takuro Saito;Hiroyoshi Nishikawa;Hisashi Wada;Yuji Nagano

  • The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.

    Shogo Kumagai;Yosuke Togashi;Takahiro Kamada;Eri Sugiyama

  • Regulatory T cells in cancer immunotherapy.

    Hiroyoshi Nishikawa;Shimon Sakaguchi

  • Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans

    Daisuke Sugiyama;Hiroyoshi Nishikawa;Yuka Maeda;Megumi Nishioka

  • Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation

    Masanori Matsumoto;Akemi Baba;Takafumi Yokota;Hiroyoshi Nishikawa

  • Roles of regulatory T cells in cancer immunity.

    Yoshiko Takeuchi;Hiroyoshi Nishikawa

  • NY-ESO-1: review of an immunogenic tumor antigen.

    Sacha Gnjatic;Hiroyoshi Nishikawa;Achim A Jungbluth;Ali O Güre

  • Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

    Kazuhiko Kakihana;Yuki Fujioka;Wataru Suda;Wataru Suda;Yuho Najima

  • Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies

    Hiroyoshi Nishikawa;Shohei Koyama

  • Tumor‐infiltrating IL‐17‐producing γδ T cells support the progression of tumor by promoting angiogenesis

    Daiko Wakita;Kentaro Sumida;Yoichiro Iwakura;Hiroyoshi Nishikawa

  • Natural and Induced T Regulatory Cells in Cancer

    Dennis O Adeegbe;Hiroyoshi Nishikawa

  • Antitumour immunity regulated by aberrant ERBB family signalling

    Shogo Kumagai;Shohei Koyama;Hiroyoshi Nishikawa

  • Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

    Koji Kurose;Yoshihiro Ohue;Hisashi Wada;Shinsuke Iida

  • CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses.

    Hiroyoshi Nishikawa;Takuma Kato;Koji Tanida;Atsunori Hiasa

  • In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.

    Hiroyoshi Nishikawa;Eiichi Sato;Gabriel Briones;Li-Mei Chen

  • CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.

    Hiroyoshi Nishikawa;Elke Jäger;Gerd Ritter;Lloyd J. Old

Frequent Co-Authors

Hiroshi Shiku
Hiroshi Shiku Mie University
Shimon Sakaguchi
Shimon Sakaguchi Osaka University
Lloyd J. Old
Lloyd J. Old Ludwig Cancer Research
Sacha Gnjatic
Sacha Gnjatic Icahn School of Medicine at Mount Sinai
Gerd Ritter
Gerd Ritter Memorial Sloan Kettering Cancer Center
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Yuichiro Doki
Yuichiro Doki Osaka University
Masaaki Ito
Masaaki Ito Mie University
Masaki Mori
Masaki Mori Kyushu University
Masahira Hattori
Masahira Hattori Waseda University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. One popular route is becoming a Licensed Practical Nurse (LPN), where students often seek the lpn programs easy to get into. These programs provide an entryway into patient care and immunology-related roles with flexible online options.

Nurse Practitioner (NP) degrees are another valuable pathway, especially for those aiming to specialize further. Many prospective students look for programs that balance quality and accessibility, which is why knowing about what is the easiest np program can help when choosing an online degree that fits their needs and timeline.

For a focus in mental health, Psychiatric Mental Health Nurse Practitioner (PMHNP) programs combine immunological and neurological insights in patient care. Finding the best pmhnp programs online ensures strong clinical placements and support throughout studies, which is key for hands-on experience.

Cost is always a consideration, and prospective students can benefit from exploring the cheapest online pmhnp programs. Affordable options help reduce financial barriers without compromising on education quality.

Best Scientists Citing Hiroyoshi Nishikawa

Trending Scientists

Recently Published Articles